- Home
- UNB vs VTYX Comparison
UNB vs VTYX Comparison
Compare UNB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- VTYX
- Stock Information
- Founded
- UNB 1891
- VTYX 2018
- Country
- UNB United States
- VTYX United States
- Employees
- UNB N/A
- VTYX N/A
- Industry
- UNB Major Banks
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- UNB Finance
- VTYX Health Care
- Exchange
- UNB Nasdaq
- VTYX Nasdaq
- Market Cap
- UNB 167.6M
- VTYX 154.9M
- IPO Year
- UNB 1998
- VTYX 2021
- Fundamental
- Price
- UNB $28.90
- VTYX $1.61
- Analyst Decision
- UNB
- VTYX Buy
- Analyst Count
- UNB 0
- VTYX 4
- Target Price
- UNB N/A
- VTYX $11.33
- AVG Volume (30 Days)
- UNB 6.0K
- VTYX 1.3M
- Earning Date
- UNB 03-04-2025
- VTYX 03-04-2025
- Dividend Yield
- UNB 4.98%
- VTYX N/A
- EPS Growth
- UNB N/A
- VTYX N/A
- EPS
- UNB 1.94
- VTYX N/A
- Revenue
- UNB $47,157,000.00
- VTYX N/A
- Revenue This Year
- UNB N/A
- VTYX N/A
- Revenue Next Year
- UNB N/A
- VTYX N/A
- P/E Ratio
- UNB $14.90
- VTYX N/A
- Revenue Growth
- UNB N/A
- VTYX N/A
- 52 Week Low
- UNB $21.00
- VTYX $1.57
- 52 Week High
- UNB $37.70
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- UNB 36.26
- VTYX 34.49
- Support Level
- UNB $31.70
- VTYX $1.57
- Resistance Level
- UNB $35.00
- VTYX $1.78
- Average True Range (ATR)
- UNB 1.58
- VTYX 0.10
- MACD
- UNB -0.30
- VTYX -0.00
- Stochastic Oscillator
- UNB 10.88
- VTYX 10.26
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.